StudyFinder

HM2023-07: Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Status: Recruiting

Description:

Talquetamab is an experimental medication being studied to see if it may be beneficial in the treatment of multiple myeloma.

I'm interested

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

• diagnosed with multiple myeloma that has not responded to treatment or has reoccurred after at least one treatment
• able to care for self with some assistance

Exclusion Criteria:

• active cancer in central nervous system or clinical symptoms
• maximum amount of steriods taken in the past two weeks (study staff will review)
• disease hasn't responded to this type of drug (anti-CD38 monoclonal antibody)

Conditions:

Cancer

Keywords:

Multiple Myeloma

Study Contact: Daniel O'Leary - dholeary@umn.edu

Principal Investigator: Daniel O'Leary

Phase: PHASE3

IRB Number: STUDY00018679

See this study on ClinicalTrials.gov

Back

Email this study information to me

Contact the study team